Clinical Trial

MAD Trial: Myopia Atropine Dose

Study acronym: MAD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-12-19; most recent amendment 2025-04-24.
Status change: Not Yet Recruiting → Recruiting 2023-01-05
Trial Details
NCT Number NCT05667454
Lead Sponsor Erasmus Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Progressive Myopia
Enrollment 550 participants
Start Date 2022-12-19
Primary Completion 2029-03-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-27